CompanyDeals

WestGene Biopharma and Cartesian Therapeutics Forge $500M+ mRNA Partnership for In Vivo CAR-T and T Cell Engager Autoimmune Therapies

Takeda's Entyvio Receives FDA Acceptance for Pediatric sBLA in Ulcerative Colitis and Crohn's Disease, Expanding Gut-Selective Biologic to Patients Aged 2+
CompanyDrug

Takeda’s Entyvio Receives FDA Acceptance for Pediatric sBLA in Ulcerative Colitis and Crohn’s Disease, Expanding Gut-Selective Biologic to Patients Aged 2+

Policy / Regulatory

China’s Four Health Regulators Issue Revised Good Clinical Practice Guidelines Effective September 2026, Strengthening Trial Oversight and Ethical Standards

Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share
Company

Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share

Policy / Regulatory

China’s National Health Commission Launches Anti-Corruption Campaign Targeting Pharmaceutical Sales and Healthcare Services Misconduct

CompanyDrug

Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership

Zai Lab Launches Commercial Rollout of Cobenfy in China Following First Nationwide Prescription for Schizophrenia Treatment
CompanyDrug

Zai Lab Launches Commercial Rollout of Cobenfy in China Following First Nationwide Prescription for Schizophrenia Treatment

CompanyDrug

Eli Lilly Secures FDA Approval for Every-Eight-Week EBGLYSS Regimen in Atopic Dermatitis, Offering Just Six Annual Injections

CompanyDeals

Laekna Therapeutics Secures $527M Global Licensing Deal with Vasque Bio for PI3Kα Inhibitor LAE118, Retaining China Rights

CompanyDrug

Antengene Launches Phase I ATTRACT Study for ATG-201 Bispecific Antibody in Autoimmune Diseases Following $1.18B UCB Licensing Deal

CompanyMedical Device

Shanghai Bio-heart Secures Israeli Registration for Iberis RDN System – World’s Only Dual-Access Renal Denervation Platform

CompanyDrug

Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise